Victory Capital Management Inc Lineage Cell Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$153 Billion
Q3 2025

A detailed history of Victory Capital Management Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 26,187 shares of LCTX stock, worth $49,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,187

Previous 27,111 3.41%

Holding current value

$49,755

Previous $24,000 87.5%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$0.87 - $1.79 $803 - $1,653	-924 Reduced 3.41%	26,187 $45,000
Q2 2025 Aug 13, 2025	SELL	$0.39 - $1.13 $115 - $334	-296 Reduced 1.08%	27,111 $24,000
Q1 2025 May 02, 2025	BUY	$0.45 - $0.72 $145 - $232	323 Added 1.19%	27,407 $12,000
Q4 2024 Feb 06, 2025	BUY	$0.5 - $0.95 $1,609 - $3,058	3,219 Added 13.49%	27,084 $13,000
Q3 2024 Nov 05, 2024	SELL	$0.8 - $1.12 $332 - $464	-415 Reduced 1.71%	23,865 $21,000

Q2 2024 Aug 05, 2024	SELL	$0.89 - $1.47 $347 - $573	-390 Reduced 1.58%	24,280 $24,000
Q1 2024 May 03, 2024	BUY	$0.86 - $1.48 $1,010 - $1,739	1,175 Added 5.0%	24,670 $36,000
Q4 2023 Feb 05, 2024	BUY	$0.91 - $1.35 $3,881 - $5,757	4,265 Added 22.18%	23,495 $25,000
Q3 2023 Nov 06, 2023	BUY	$1.16 - $1.53 $932 - $1,230	804 Added 4.36%	19,230 $22,000
Q2 2023 Jul 27, 2023	SELL	$1.26 - $1.53 $539 - $654	-428 Reduced 2.27%	18,426 $25,000
Q1 2023 May 02, 2023	SELL	$1.2 - $1.53 $262 - $335	-219 Reduced 1.15%	18,854 $28,000
Q4 2022 Feb 09, 2023	SELL	$1.02 - $1.5 $7 - $10	-7 Reduced 0.04%	19,073 $22,000
Q3 2022 Nov 02, 2022	SELL	$1.13 - $1.77 $4,035 - $6,320	-3,571 Reduced 15.77%	19,080 $22,000
Q2 2022 Aug 01, 2022	BUY	$1.12 - $1.61 $269 - $388	241 Added 1.08%	22,651 $36,000
Q1 2022 May 04, 2022	SELL	$1.21 - $2.48 $1,366 - $2,799	-1,129 Reduced 4.8%	22,410 $27,000
Q4 2021 Feb 07, 2022	SELL	$1.84 - $2.68 $1,056 - $1,538	-574 Reduced 2.38%	23,539 $58,000
Q3 2021 Nov 02, 2021	SELL	$2.26 - $2.86 $935 - $1,184	-414 Reduced 1.69%	24,113 $61,000
Q2 2021 Aug 03, 2021	BUY	$2.17 - $3.0 $2,458 - $3,399	1,133 Added 4.84%	24,527 $70,000
Q1 2021 May 04, 2021	SELL	$1.77 - $3.1 $1,288 - $2,256	-728 Reduced 3.02%	23,394 $55,000
Q4 2020 Feb 01, 2021	BUY	$0.95 - $1.83 $1,171 - $2,256	1,233 Added 5.39%	24,122 $42,000
Q3 2020 Nov 09, 2020	SELL	$0.75 - $1.09 $970 - $1,410	-1,294 Reduced 5.35%	22,889 $21,000
Q2 2020 Aug 07, 2020	SELL	$0.71 - $1.18 $516 - $857	-727 Reduced 2.92%	24,183 $21,000
Q1 2020 May 04, 2020	SELL	$0.6 - $1.58 $338 - $891	-564 Reduced 2.21%	24,910 $21,000
Q4 2019 Feb 04, 2020	SELL	$0.54 - $1.01 $212 - $396	-393 Reduced 1.52%	25,474 $26,000
Q3 2019 Nov 12, 2019	BUY	$0.85 - $1.24 $21,986 - $32,075	25,867 New	25,867 $25,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Lineage Cell Therapeutics, Inc. Transaction History